eCite Digital Repository

Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease (Intervention Review)

Citation

Walters, JAE and Smith, S and Poole, P and Granger, RH and Wood-Baker, R, Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease (Intervention Review), Cochrane Database of Systematic Reviews, 2010, (11) EJ ISSN 1469-493X (2010) [Refereed Article]


Preview
PDF
Restricted - Request a copy
582Kb
  

Copyright Statement

The definitive published version is available online at: http://onlinelibrary.wiley.com/

Official URL: http://onlinelibrary.wiley.com/o/cochrane/clsysrev...

DOI: doi:10.1002/14651858.CD001390.pub3

Abstract

Background As chronic obstructive pulmonary disease (COPD) progresses, exacerbations can occur with increasing frequency.One goal of therapy is to prevent these exacerbations, thereby reducing morbidity and associated healthcare costs. Pneumococcal vaccinations are one strategy for reducing the risk of infective exacerbations. Objectives To determine the safety and efficacy of pneumococcal vaccination inCOPD.The primary outcomes assessedwere episodes of pneumonia and acute exacerbations. Secondary outcomes of interest included hospital admissions, adverse events related to treatment, disability, change in lung function, mortality, and cost effectiveness. Search strategy We searched the Cochrane Airways Group COPD trials register and the databases CENTRAL, MEDLINE and EMBASE using prespecified terms. The latest searches were performed in March 2010. Selection criteria Randomised controlled trials assessing the effects of injectable pneumococcal vaccine in people with COPD were included. Data collection and analysis Two review authors independently extracted data and three review authors independently assessed trial quality. Main results Seven studies were identified that met the inclusion criteria for this review and were included in the 2010 review update. Two older trials used a 14-valent vaccine and five more recent trials used a 23-valent injectable vaccine. In six studies involving 1372 people, the reduction in likelihood of developing pneumonia with pneumococcal vaccination compared to control did not achieve statistical significance, the odds ratio (OR) was 0.72 (95%confidence interval (CI) 0.51 to 1.01), with moderate heterogeneity present between studies. The reduction in likelihood of acute exacerbations of COPD from two studies involving 216 people was not statistically significant (Peto OR 0.58; 95% CI 0.30 to 1.13). Of the secondary outcomes for which data were available there was no statistically significant effect for reduction in hospital admissions (two studies) or emergency department visits (one study). There was no significant reduction in pooled results from three studies involving 888 people for odds of all-cause mortality for periods up to 48 months post-vaccination (OR 0.94; 95% CI 0.67 to 1.33), or for death from cardiorespiratory causes (OR 1.07; 95% CI 0.69 to 1.66).

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Cardiorespiratory Medicine and Haematology
Research Field:Respiratory Diseases
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Respiratory System and Diseases (incl. Asthma)
Author:Walters, JAE (Dr Julia Walters)
Author:Smith, S ( Smith)
Author:Wood-Baker, R (Professor Richard Wood-Baker)
ID Code:66703
Year Published:2010
Web of Science® Times Cited:27
Deposited By:Menzies Institute for Medical Research
Deposited On:2011-02-08
Last Modified:2011-05-03
Downloads:1 View Download Statistics

Repository Staff Only: item control page